Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance
Justin R. Bailey, … , Steven K.H. Foung, Stuart C. Ray
Justin R. Bailey, … , Steven K.H. Foung, Stuart C. Ray
Published December 15, 2014
Citation Information: J Clin Invest. 2015;125(1):437-447. https://doi.org/10.1172/JCI78794.
View: Text | PDF
Research Article

Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance

  • Text
  • PDF
Abstract

For hepatitis C virus (HCV) and other highly variable viruses, broadly neutralizing mAbs are an important guide for vaccine development. The development of resistance to anti-HCV mAbs is poorly understood, in part due to a lack of neutralization testing against diverse, representative panels of HCV variants. Here, we developed a neutralization panel expressing diverse, naturally occurring HCV envelopes (E1E2s) and used this panel to characterize neutralizing breadth and resistance mechanisms of 18 previously described broadly neutralizing anti-HCV human mAbs. The observed mAb resistance could not be attributed to polymorphisms in E1E2 at known mAb-binding residues. Additionally, hierarchical clustering analysis of neutralization resistance patterns revealed relationships between mAbs that were not predicted by prior epitope mapping, identifying 3 distinct neutralization clusters. Using this clustering analysis and envelope sequence data, we identified polymorphisms in E2 that confer resistance to multiple broadly neutralizing mAbs. These polymorphisms, which are not at mAb contact residues, also conferred resistance to neutralization by plasma from HCV-infected subjects. Together, our method of neutralization clustering with sequence analysis reveals that polymorphisms at noncontact residues may be a major immune evasion mechanism for HCV, facilitating viral persistence and presenting a challenge for HCV vaccine development.

Authors

Justin R. Bailey, Lisa N. Wasilewski, Anna E. Snider, Ramy El-Diwany, William O. Osburn, Zhenyong Keck, Steven K.H. Foung, Stuart C. Ray

×

Figure 7

V538I/L546Q/V563T mutations in E2 confer additive sensitivity to NC1 mAbs.

Options: View larger image (or click on image) Download as PowerPoint
V538I/L546Q/V563T mutations in E2 confer additive sensitivity to NC1 mAb...
(A) Alignment of amino acids 526–569 of sensitive E1E2 clone 1b09 and resistant clones 1a129 and 1a142. Homology to the 1b09 amino acid sequence is indicated by a dot. Positions that differ between the sensitive and both resistant clones are highlighted in yellow. Arrows indicate contact residues for AR3C in the E2 core/AR3C crystal structure. (B) The dashed line indicates relative infection of HCVpp with chimeric E1E2 1b09/1a129-β in the presence of the mab AR3A, adjusted to 1. Each subsequent bar indicates the fold change in neutralization resistance after the indicated mutation(s) were introduced. Error bars indicate SD between duplicate wells. (C) Neutralization by serial dilutions of the indicated mAb of HCVpp with chimeric E1E2 1b09/1a129-β (pp1b09/1a129-β) or pp1b09/1a129-β after introduction of the indicated mutation(s). Error bars indicate SD between duplicate wells.
Follow JCI:
Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts